Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Le, Mai T Q ^a   Wertheim, Heiman F L ^b,g   Nguyen, Hien D ^c   Taylor, Walter ^b,g   Hoang, Phuong V M ^a   Vuong, Cuong D ^a   Nguyen, Hang L K ^a   Nguyen, Ha H ^c   Nguyen, Thai Q ^c   Nguyen, Trung V ^c   Van, Trang D ^c   Ngoc, Bich T ^b   Bui, Thinh N ^d   Nguyen, Binh G ^d   Nguyen, Liem T ^e   Luong, San T ^e   Phan, Phuc H ^e   Pham, Hung V ^e   Nguyen, Tung ^f   Fox, Annette ^b,g   Nguyen, Cam V ^f   Do, Ha Q ^b,g   Crusat, Martin ^b,g   Farrar, Jeremy ^b,g   Nguyen, Hien T ^a   de Jong, Menno D ^b,g   Horby, Peter ^b,g   more..

^a NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c National Institute for Infectious and Tropical Diseases   (Viet Nam)

^d BACH MAI HOSPITAL   (Viet Nam)

^e NATIONAL HOSPITAL OF PEDIATRICS   (Viet Nam)

^f National Center for Veterinary Diagnosis   (Viet Nam)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; PROTEIN M2; SIALIDASE; STEROID; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AVIAN INFLUENZA; CHILD; CLADISTICS; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; POULTRY; VIET NAM; VIRUS GENE; VIRUS ISOLATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CLASSIFICATION; DRUG EFFECT; EPIDEMIC; GENETICS; GEOGRAPHY; INFLUENZA; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VIROLOGY;

AVES;

ADOLESCENT; ADULT; AMANTADINE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; FEMALE; GEOGRAPHY; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; PHYLOGENY; RETROSPECTIVE STUDIES; VIETNAM;

EID: 53749085251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003339     Document Type: Article

References (22)

1. Peiris JS, de Jong MD, Guan Y (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20: 243-267.
2. Smith GJ, Naipospos TS, Nguyen TD, de Jong MD, Vijaykrishna D, et al. (2006) Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology 350: 258-268.
3. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
4. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11: 1515-1521.
5. Nguyen TD, Nguyen TV, Vijaykrishna D, Webster RG, Guan Y, et al. (2008) Multiple sublineages of Influenza A virus (H5N1), Vietnam, 2005-2007. Emerg Infect Dis 14: 632-636.
6. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, et al. (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73: 228-231.
7. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
8. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
9. Pfeiffer DU, Minh PQ, Martin V, Epprecht M, Otte MJ (2007) An analysis of the spatial and temporal patterns of highly pathogenic avian influenza occurrence in Vietnam using national surveillance data. Vet J 174: 302-309.
10. Dinh PN, Long HT, Tien NT, Hien NT, Mai le TQ, et al. (2006) Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 12: 1841-1847.
11. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, et al. (2005) Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352: 686-691.
12. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, et al. (2000) Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 280: 291-300.
13. Gubareva LV, Webster RG, Hayden FG (2002) Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 53: 47-61.
14. Smith GJ, Fan XH, Wang J, Li KS, Qin K, et al. (2006) Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A 103: 16936-16941.
15. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 13: 1354-1357.
16. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193: 1626-1629.
17. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370.
18. Morrison D, Roy S, Rayner C, Amer A, Howard D, et al. (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2: e1305.
19. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121-131.
20. Clinical management of human infection with avian influenza A (H5N1) virus. World Health Organization Updated advice 15 august 2007 ( http://wwww.hoint/csr/disease/avian_influenza/guidelines/ ClinicalManagement07pdf).
21. Hayden FG, Pavia AT (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 194 Suppl 2: S119-126.
22. He G, Qiao J, Dong C, He C, Zhao L, et al. (2008) Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 77: 72-76.